Loan Agreement

Proteome Sciences plc                             

                                ("The Company")                                

Cobham, England (June 24, 2008) - The Directors of Proteome Sciences plc are
pleased to announce that following the release of the preliminary announcement
of the results for the year to the 31st December, 2007, the Company has entered
into a further loan agreement with C.D.J. Pearce, the Chief Executive of the
Company, under which the amount of the facility available has been increased to
up to £8m. The agreement is on the same terms as the loan agreement dated 21st
February, 2008 save that security for the total loan facility includes a
floating charge over the company's stock-in-trade.

In relation to the increase in the loan facility from C.D.J. Pearce, the
Directors of the Company, (with the exception of C.D.J. Pearce who, in view of
his interest in the transaction, has taken no part in the consideration
thereof), having consulted with its nominated adviser, consider that the terms
of this transaction are fair and reasonable insofar as shareholders are
concerned.

The Report and Accounts for 2007 will be posted to shareholders on the 27th
June and the Annual General Meeting will be held on Monday 28th July, 2008.

                                     Ends                                      

About Proteome Sciences:

Proteome Sciences plc (LSE : PRM) is a global leader in applied proteomics,
using high sensitivity proprietary techniques to detect and characterise
differentially expressed proteins in diseases for diagnostic, prognostic and
therapeutic applications.

ProteoSHOP® provides integrated proteomic services for biomarker discovery,
validation and measurement in clinical trials and in vitro diagnostics. Key
features include the proprietary isobaric tandem mass tag technology TMT® for
accurate and reliable biomarker quantification and the ability to rapidly
develop highly reproducible quantitative biomarker assays.

The main focus of its research addresses neurological, oncology and
cardiovascular conditions and has discovered blood biomarkers in stroke, brain
damage, solid organ transplant rejection and Alzheimer's disease. Proteome
Sciences is based in Cobham, UK with facilities in London and Frankfurt.

Contact Proteome Sciences plc at www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director

Tel: [phone]

Adrian Shaw, IKON Associates

Tel: [phone]

Matt Baldwin, COAST Communications

Tel: [phone]

Landsbanki Securities (UK) Limited

Shaun Dobson

Claes Spång

Tel: [phone]